Caricamento...
Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression
OBJECTIVE: Preclinical evidence indicates that rapid changes in levels of allopregnanolone, the predominant metabolite of progesterone, confer dramatic behavioral changes and may trigger postpartum depression (PPD) in some women. Considering the pathophysiology of PPD (i.e., triggered by reproductiv...
Salvato in:
| Pubblicato in: | Hum Psychopharmacol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5396368/ https://ncbi.nlm.nih.gov/pubmed/28370307 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hup.2576 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|